Review

mac2 antibody (Cedarlane)

Cedarlane is a verified supplier

Cedarlane manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Cedarlane mac2 antibody
Mac2 Antibody, supplied by Cedarlane, used in various techniques. Bioz Stars score: 96/100, based on 398 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/m3+38/Anti-Mouse%2FHuman+Mac-2+(Galectin-3)%2C+Purified+(Clone+M3%2F38)+(rat+IgG2a)/pm42831433-192-14-16
Average 96 stars, based on 398 article reviews

mac2 antibody - by Bioz Stars, 2026-10

96/100 stars

Images

other:

Article Title: Hyperglycemia Induced by Glucokinase Deficiency Accelerates Atherosclerosis Development and Impairs Lesion Regression in Combined Heterozygous Glucokinase and the Apolipoprotein E-Knockout Mice.
Article Snippet: See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense 1 : 10000, clone M3/38, CL8942AP, Cedarlane) using DAB (BC-BDB2004, Biocare) as the chromogen.

Article Title: Spinal muscular atrophy-like phenotype in a mouse model of acid ceramidase deficiency
Article Snippet: Plasmids were propagated in XL10-gold ultracompetent cells (Agilent 200314) and were purified using a miniprep kit (Qiagen 27104).

Article Title: Neural crest stem cells protect spinal cord neurons from excitotoxic damage and inhibit glial activation by secretion of brain-derived neurotrophic factor
Article Snippet: Anti-mouse MAC-II FITC or biotin conjugated , CLCR2A01, clone M3/38 , Cederlane Burlington NC USA, CL8942F (or B), AB_10060162 (or AB_10059939), rat monoclonal , 1:400.

Article Title: B cell-derived nociceptin/orphanin FQ contributes to impaired glucose tolerance and insulin resistance in obesity
Article Snippet: MAC-2 and Gal-3 (Galectin-3) Monoclonal antibody, Unconjugated, Clone m3/38 , Cedarlane , Cat# CL8942AP; RRID: AB_10060357.

Immunohistochemistry:

Article Title: Hepatic pathology and altered gene transcription in a murine model of acid ceramidase deficiency.
Article Snippet: .. For liver immunohistochemistry (IHC), the following primary antibodies were used: anti-mouse neutrophil (Ly-6B.2) clone 7/4 (Cedarlane, Burlington, Canada) and rat antimouse Mac-2 (Galectin-3) clone M3/38 (Cedarlane), rabbit anti-cleaved caspase-3 (Cell Signaling Technology, Danvers, MA), and rabbit anti-Ki-67 (Thermo Scientific). .. In situ detection of cell death was performed via a Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay (Promega, Madison, WI).

Article Title: Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency
Article Snippet: .. Liver IHC was performed using the following primary antibodies: anti-mouse neutrophil, clone 7/4 (Cedarlane, Burlington, Canada) and rat anti-mouse Mac-2 (Galectin-3) clone M3/38 (Cedarlane). .. For brain analyses, tissue sections were stained with H&E and IHC was performed using the following primary antibodies: rabbit anti-ionized, calcium-binding adaptor molecule 1 (Iba-1) (Wako Chemicals USA, Cambridge, MA) and chicken anti-glial fibrillary acidic protein (GFAP) (Aves Lab Inc, Tigard, OR).

Article Title: Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency.
Article Snippet: .. Liver IHC was performed using the following primary antibodies: anti-mouse neutrophil, clone 7/4 (Cedarlane, Burlington, Canada) and rat anti-mouse Mac-2 (Galectin-3) clone M3/38 (Cedarlane). .. For brain analyses, tissue sections were stained with H&E and IHC was performed using the following primary antibodies: rabbit anti-ionized, 1 4SCIeNTIfIC REPORtS | (2018) 8:1808 | DOI:10.1038/s41598-018-20052-6 calcium-binding adaptor molecule 1 (Iba-1) (Wako Chemicals USA, Cambridge, MA) and chicken anti-glial fibrillary acidic protein (GFAP) (Aves Lab Inc, Tigard, OR).

Staining:

Article Title: Endothelial hyaluronan synthase 3 aggravates acute colitis in an experimental model of inflammatory bowel disease.
Article Snippet: The association between hyaluronan (HA) accumulation and increased inflammation in the colon suggests that HA is a potential therapeutic target in inflammatory bowel disease (IBD).. However, whether patients with IBD would benefit from interference with HA synthesis is unknown.. Here, we used pharmacological and genetic approaches to investigate the impact of systemic and partial blockade of HA synthesis in the Dextran Sodium Sulfate (DSS)-induced colitis model. To systemically inhibit HA production, we used 4-Methylumbelliferone (4-MU), whereas genetic approaches included the generation of mice with global or inducible cell-type specific deficiency in the Hyaluronan synthase 3 (Has3).

Image Search Results

Atherosclerosis regression is incomplete in Jak2 VF MPN mice with moderate cholesterol lowering. A: Study design created with BioRender.com. B: Plasma cholesterol (n = 34, 55, 55, 54, 16, 16 for Ctrl mice, n = 31, 55, 49, 39, 17, 16 for Jak2 VF mice, for weeks 0, 5, 11, 15, 17.5, 21 respectively). P = 0.028, <0.0001, <0.0001, <0.0001, 0.0005, <0.0001 (Ctrl vs. Jak2 VF at weeks 0, 5, 11, 15, 17.5, and 21, respectively). C: H&E images of aortic root lesions. Black lines , necrotic core. Scale bar, 200 μm. D: Lesion area, n = 15–23. P < 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline; Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.052 ( Jak2 VF Baseline vs. LDL Lowering). E: Necrotic core area, n = 15–23. P = 0.0079 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0002 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.0003 ( Jak2 VF Baseline vs. LDL Lowering). F: Picrosirius red-stained aortic root lesions. Scale bar, 200 μm. G: Collagen area as a percentage of lesion area, n = 15–24. P = 0.02 (Ctrl Baseline vs. LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ) and DAPI ( Blue ). Scale bar, 200 μm. I: Macrophage area, n = 15–24. P = 0.006 (Ctrl Baseline vs. LDL Lowering), P = 0.16 ( Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with the Geisser-Greenhouse correction for sphericity and Tukey’s multiple comparisons test (B). Two-way ANOVA with Tukey’s multiple comparisons test (D, E, G, and I). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Atherosclerosis regression is incomplete in Jak2 VF MPN mice with moderate cholesterol lowering. A: Study design created with BioRender.com. B: Plasma cholesterol (n = 34, 55, 55, 54, 16, 16 for Ctrl mice, n = 31, 55, 49, 39, 17, 16 for Jak2 VF mice, for weeks 0, 5, 11, 15, 17.5, 21 respectively). P = 0.028, <0.0001, <0.0001, <0.0001, 0.0005, <0.0001 (Ctrl vs. Jak2 VF at weeks 0, 5, 11, 15, 17.5, and 21, respectively). C: H&E images of aortic root lesions. Black lines , necrotic core. Scale bar, 200 μm. D: Lesion area, n = 15–23. P < 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline; Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.052 ( Jak2 VF Baseline vs. LDL Lowering). E: Necrotic core area, n = 15–23. P = 0.0079 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0002 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.0003 ( Jak2 VF Baseline vs. LDL Lowering). F: Picrosirius red-stained aortic root lesions. Scale bar, 200 μm. G: Collagen area as a percentage of lesion area, n = 15–24. P = 0.02 (Ctrl Baseline vs. LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ) and DAPI ( Blue ). Scale bar, 200 μm. I: Macrophage area, n = 15–24. P = 0.006 (Ctrl Baseline vs. LDL Lowering), P = 0.16 ( Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with the Geisser-Greenhouse correction for sphericity and Tukey’s multiple comparisons test (B). Two-way ANOVA with Tukey’s multiple comparisons test (D, E, G, and I). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm.

Article Snippet: Following blocking, sections were incubated with the following primary antibodies at the indicated concentrations overnight at 4 °C in a humidified chamber: Absent in melanoma 2 (AIM2) (Abcam, ab119791, 1:250), Cleaved GasD (Cell Signaling, 10137, 10 μg/ml), c-Myc (Cell Signaling, 5605, 5.76 μg/ml), Ki67 (Abcam, ab15580, 9 μg/ml), MAC2 (Cedarlane, CL8942AP 1 μg/ml), MAC2 conjugated to Alexa Fluor 488 (Cedarlane, CL8942AF4, 1 μg/ml), mer proto-oncogene tyrosine kinase (MerTK) (R&D, BAF591, 2 μg/ml), pγH2AX (Cell Signaling, 9718, 0.74 μg/ml), ZsGreen (Thermo Fisher Scientific, TA180002, 10 μg/ml), triggering receptor expressed on myeloid cells 2 (TREM2) (Denali, 4D9 DC1847, 1:100).

Techniques: Clinical Proteomics, Staining

Aggressive cholesterol lowering normalizes regression in Jak2 VF MPN lesions. A: Study design, created with BioRender.com. B: Plasma cholesterol (n = 5, 38, 19, 18, and 18 for Ctrl mice, n = 5, 37, 15, 16, and 15 for Jak2 VF mice, for weeks 0, 4, 13, 15, and 18, respectively). P = 0.0041 for genotype effect by two-way ANOVA with Geisser-Greenhouse correction, P = 0.011, 0.048, 0.056, and 0.0008 (Ctrl vs. Jak2 VF at weeks 0, 4, 13, and 15, respectively). C: H&E images of aortic root lesions. Black lines , necrotic core. Scale bar, 200 μm. D: Lesion area, n = 13–20. P < 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline; Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). Figures 1 and 4 represent independent regression cohorts performed separately; therefore, absolute lesion area should be compared within each cohort rather than between figures. E: Necrotic core area, n = 13–20. P = 0.0003 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0006 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.90 ( Jak2 VF Baseline vs. LDL Lowering). F: Picrosirius red-stained aortic root lesions. Scale bar, 200 μm. G: Collagen area as a percentage of lesion area, n = 13–20. P < 0.0001 (Ctrl Baseline vs. LDL Lowering), P = 0.0002 ( Jak2 VF Baseline vs. LDL Lowering), P = 0.02 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ) and DAPI ( Blue ). Scale bar, 200 μm. I: Macrophage area, n = 13–20. P < 0.0001 (Ctrl and Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (D, G, and I). Two-way ANOVA with the Geisser-Greenhouse correction for sphericity and Tukey’s multiple comparisons test (B). Kruskal-Wallis test with Dunn’s multiple comparisons test (E). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Aggressive cholesterol lowering normalizes regression in Jak2 VF MPN lesions. A: Study design, created with BioRender.com. B: Plasma cholesterol (n = 5, 38, 19, 18, and 18 for Ctrl mice, n = 5, 37, 15, 16, and 15 for Jak2 VF mice, for weeks 0, 4, 13, 15, and 18, respectively). P = 0.0041 for genotype effect by two-way ANOVA with Geisser-Greenhouse correction, P = 0.011, 0.048, 0.056, and 0.0008 (Ctrl vs. Jak2 VF at weeks 0, 4, 13, and 15, respectively). C: H&E images of aortic root lesions. Black lines , necrotic core. Scale bar, 200 μm. D: Lesion area, n = 13–20. P < 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline; Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). Figures 1 and 4 represent independent regression cohorts performed separately; therefore, absolute lesion area should be compared within each cohort rather than between figures. E: Necrotic core area, n = 13–20. P = 0.0003 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0006 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering), P = 0.90 ( Jak2 VF Baseline vs. LDL Lowering). F: Picrosirius red-stained aortic root lesions. Scale bar, 200 μm. G: Collagen area as a percentage of lesion area, n = 13–20. P < 0.0001 (Ctrl Baseline vs. LDL Lowering), P = 0.0002 ( Jak2 VF Baseline vs. LDL Lowering), P = 0.02 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ) and DAPI ( Blue ). Scale bar, 200 μm. I: Macrophage area, n = 13–20. P < 0.0001 (Ctrl and Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (D, G, and I). Two-way ANOVA with the Geisser-Greenhouse correction for sphericity and Tukey’s multiple comparisons test (B). Kruskal-Wallis test with Dunn’s multiple comparisons test (E). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm.

Techniques: Clinical Proteomics, Staining

Cholesterol lowering suppresses Jak2 VF macrophage proliferation and DNA damage. A: Study design created with BioRender.com. B: Plasma cholesterol (n = 79, 78, and 78 for Baseline mice for weeks 3, 11, and 15, respectively; n = 13, 14 for Ctrl Progression mice, n = 16, 16 for Ctrl LDL Lowering mice, n = 15, 15 for Jak2 VF Progression mice, n = 16, 16 for Jak2 VF LDL Lowering mice, for weeks 18 and 23, respectively). C: Images of aortic root lesions for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. D: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in lesions with the addition of constant 1, n = 14–16. P = 0.01 (Baseline vs. Jak2 VF Progression), P = 0.051 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). E: Log 10 transformed cleaved GasD MFI in the necrotic core with the addition of constant 1, n = 14–16. P = 0.04 (Baseline vs. Jak2 VF Progression), P = 0.013 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). F: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. G: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 14–16. H: Images of aortic root lesions for MAC2 ( Red ), Ki67 ( White ), and ZsGreen ( Green ). Scale bar, 60 μm. White arrows , macrophages double positive for Ki67 and ZsGreen. I: Macrophages positive for both Ki67 and ZsGreen per section, n = 13–15. P = 0.0019 (Baseline vs. Jak2 VF Progression), P = 0.0006 (Ctrl Progression vs. Jak2 VF Progression), P = 0.0003 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). J: Macrophages positive for Ki67 but negative for ZsGreen per section, n = 13–16. K: Images of aortic root lesions stained for pγH2AX ( Red ), ZsGreen ( Green ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows, pγH2AX positive cells. L: Log 10 transformed cells double positive for pγH2AX and ZsGreen in lesions with the addition of constant 1, n = 13–16. P = 0.0024 (Baseline vs. Jak2 VF Progression), P = 0.0019 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). M: Log 10 transformed cells positive for pγH2AX but negative for ZsGreen in lesions with the addition of constant 1, n = 13–16. All quantifications shown as mean ± s.e.m. One-way ANOVA with Holm–Sidak’s multiple comparisons test (D and E). Kruskal–Wallis test with Dunn’s multiple comparison’s test (G, I, J, L, and M). DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; pγH2AX, phosphorylated histone H2A.X.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Cholesterol lowering suppresses Jak2 VF macrophage proliferation and DNA damage. A: Study design created with BioRender.com. B: Plasma cholesterol (n = 79, 78, and 78 for Baseline mice for weeks 3, 11, and 15, respectively; n = 13, 14 for Ctrl Progression mice, n = 16, 16 for Ctrl LDL Lowering mice, n = 15, 15 for Jak2 VF Progression mice, n = 16, 16 for Jak2 VF LDL Lowering mice, for weeks 18 and 23, respectively). C: Images of aortic root lesions for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. D: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in lesions with the addition of constant 1, n = 14–16. P = 0.01 (Baseline vs. Jak2 VF Progression), P = 0.051 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). E: Log 10 transformed cleaved GasD MFI in the necrotic core with the addition of constant 1, n = 14–16. P = 0.04 (Baseline vs. Jak2 VF Progression), P = 0.013 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). F: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. G: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 14–16. H: Images of aortic root lesions for MAC2 ( Red ), Ki67 ( White ), and ZsGreen ( Green ). Scale bar, 60 μm. White arrows , macrophages double positive for Ki67 and ZsGreen. I: Macrophages positive for both Ki67 and ZsGreen per section, n = 13–15. P = 0.0019 (Baseline vs. Jak2 VF Progression), P = 0.0006 (Ctrl Progression vs. Jak2 VF Progression), P = 0.0003 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). J: Macrophages positive for Ki67 but negative for ZsGreen per section, n = 13–16. K: Images of aortic root lesions stained for pγH2AX ( Red ), ZsGreen ( Green ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows, pγH2AX positive cells. L: Log 10 transformed cells double positive for pγH2AX and ZsGreen in lesions with the addition of constant 1, n = 13–16. P = 0.0024 (Baseline vs. Jak2 VF Progression), P = 0.0019 ( Jak2 VF Progression vs. Jak2 VF LDL Lowering). M: Log 10 transformed cells positive for pγH2AX but negative for ZsGreen in lesions with the addition of constant 1, n = 13–16. All quantifications shown as mean ± s.e.m. One-way ANOVA with Holm–Sidak’s multiple comparisons test (D and E). Kruskal–Wallis test with Dunn’s multiple comparison’s test (G, I, J, L, and M). DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; pγH2AX, phosphorylated histone H2A.X.

Techniques: Clinical Proteomics, Transformation Assay, Fluorescence, Staining

Moderate cholesterol lowering reverses macrophage AIM2 inflammasome activation, DNA damage, and proliferation in Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in lesions with the addition of constant 1, n = 15–24. P = 0.021 (Ctrl Baseline vs. Jak2 VF Baseline). C: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in necrotic cores with the addition of constant 1, n = 15–24. P = 0.0008 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.032 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). D: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. E: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 15–24. P = 0.024 ( Jak2 VF Baseline vs. LDL Lowering). F: Images of aortic root lesions stained for MAC2 ( Green ), AIM2 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , AIM2 positive macrophages. G: Log 10 transformed AIM2 positive macrophages per section with the addition of constant 1, n = 15–23. P = 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.03 ( Jak2 VF Baseline vs. LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ), pγH2AX ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , pγH2AX positive cells. I: Log 10 transformed pγH2AX positive cells per section with the addition of constant 1, n = 15–23. P = 0.0019 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.045 ( Jak2 VF Baseline vs. LDL Lowering). J: Images of aortic root lesions stained for MAC2 ( Green ), Ki67 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , Ki67 positive macrophages. K: Log 10 transformed Ki67 positive macrophages per section with the addition of constant 1, n = 15–23. P = 0.0019 ( Jak2 VF Baseline vs. LDL Lowering). MAC2 intensity differences reflect independent staining and imaging sessions across panels. All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (B and C). Kruskal–Wallis test with Dunn’s multiple comparisons test (E, G, I, and K). AIM2, absent in melanoma 2; DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm; pγH2AX, phosphorylated histone H2A.X.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Moderate cholesterol lowering reverses macrophage AIM2 inflammasome activation, DNA damage, and proliferation in Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in lesions with the addition of constant 1, n = 15–24. P = 0.021 (Ctrl Baseline vs. Jak2 VF Baseline). C: Log 10 transformed cleaved GasD mean fluorescence intensity (MFI) in necrotic cores with the addition of constant 1, n = 15–24. P = 0.0008 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.032 (Ctrl LDL Lowering vs. Jak2 VF LDL Lowering). D: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. E: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 15–24. P = 0.024 ( Jak2 VF Baseline vs. LDL Lowering). F: Images of aortic root lesions stained for MAC2 ( Green ), AIM2 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , AIM2 positive macrophages. G: Log 10 transformed AIM2 positive macrophages per section with the addition of constant 1, n = 15–23. P = 0.0001 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.03 ( Jak2 VF Baseline vs. LDL Lowering). H: Images of aortic root lesions stained for MAC2 ( Green ), pγH2AX ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , pγH2AX positive cells. I: Log 10 transformed pγH2AX positive cells per section with the addition of constant 1, n = 15–23. P = 0.0019 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.045 ( Jak2 VF Baseline vs. LDL Lowering). J: Images of aortic root lesions stained for MAC2 ( Green ), Ki67 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , Ki67 positive macrophages. K: Log 10 transformed Ki67 positive macrophages per section with the addition of constant 1, n = 15–23. P = 0.0019 ( Jak2 VF Baseline vs. LDL Lowering). MAC2 intensity differences reflect independent staining and imaging sessions across panels. All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (B and C). Kruskal–Wallis test with Dunn’s multiple comparisons test (E, G, I, and K). AIM2, absent in melanoma 2; DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; MPN, myeloproliferative neoplasm; pγH2AX, phosphorylated histone H2A.X.

Techniques: Activation Assay, Staining, Transformation Assay, Fluorescence, Imaging

Moderate cholesterol lowering reverses impaired efferocytosis in Jak2 VF MPN lesions while increasing TREM2 Hi macrophages in control and Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), MerTK ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Percentage of MAC2 positive area double positive for MerTK and MAC2, n = 15–23. P = 0.02 (Ctrl Baseline vs. Jak2 VF Baseline), P < 0.0001 ( Jak2 VF Baseline vs. LDL Lowering). C: Images of aortic root lesions stained for MAC2 ( Green ), TREM2 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. D: Percentage of MAC2 positive area double positive for TREM2 and MAC2, n = 15–24. P < 0.0001 (Ctrl and Jak2 VF Baseline vs. LDL Lowering). E: Images of in situ efferocytosis in aortic root lesions: MAC2 ( Green ), TUNEL ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , nuclei double positive for TUNEL and MAC2. White wedges , nuclei positive for TUNEL but negative for MAC2. F: Percentage of TUNEL positive nuclei also positive for MAC2. P = 0.011 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.021 ( Jak2 VF Baseline vs. LDL Lowering). MAC2 intensity differences reflect independent staining and imaging sessions across panels, n = 13–24. All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (D). Kruskal-Wallis test with Dunn’s multiple comparisons test (B and F). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MerTK, mer proto-oncogene tyrosine kinase; MPN, myeloproliferative neoplasm; TREM2, triggering receptor expressed on myeloid cells 2.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Moderate cholesterol lowering reverses impaired efferocytosis in Jak2 VF MPN lesions while increasing TREM2 Hi macrophages in control and Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), MerTK ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Percentage of MAC2 positive area double positive for MerTK and MAC2, n = 15–23. P = 0.02 (Ctrl Baseline vs. Jak2 VF Baseline), P < 0.0001 ( Jak2 VF Baseline vs. LDL Lowering). C: Images of aortic root lesions stained for MAC2 ( Green ), TREM2 ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. D: Percentage of MAC2 positive area double positive for TREM2 and MAC2, n = 15–24. P < 0.0001 (Ctrl and Jak2 VF Baseline vs. LDL Lowering). E: Images of in situ efferocytosis in aortic root lesions: MAC2 ( Green ), TUNEL ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , nuclei double positive for TUNEL and MAC2. White wedges , nuclei positive for TUNEL but negative for MAC2. F: Percentage of TUNEL positive nuclei also positive for MAC2. P = 0.011 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.021 ( Jak2 VF Baseline vs. LDL Lowering). MAC2 intensity differences reflect independent staining and imaging sessions across panels, n = 13–24. All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (D). Kruskal-Wallis test with Dunn’s multiple comparisons test (B and F). DAPI, 4′,6-diamidino-2-phenylindole; LDL, low-density lipoprotein; MerTK, mer proto-oncogene tyrosine kinase; MPN, myeloproliferative neoplasm; TREM2, triggering receptor expressed on myeloid cells 2.

Techniques: Control, Staining, In Situ, TUNEL Assay, Imaging

Aggressive cholesterol lowering more strongly decreases macrophage pyroptosis and DNA damage in Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Log 10 transformed cleaved GasD MFI in the necrotic core with the addition of constant 1, n = 14–20. P = 0.0064 for genotype effect and P = 0.021 for treatment effect by two-way ANOVA. C: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. D: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 13–20. P = 0.023 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.005 ( Jak2 VF Baseline vs. LDL Lowering). E: Representative immunoblot analysis of full-length and cleaved GasD in CD11b + splenocytes. F: Log 10 transformed densitometric quantification of the ratio of cleaved GasD to full-length GasD from E with the addition of constant 1. n = 7–8 biological replicates. P = 0.0003 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0046 ( Jak2 VF Baseline vs. LDL Lowering). G: Images of aortic root lesions stained for MAC2 ( Green ), pγH2AX ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , pγH2AX positive cells. H: Log 10 transformed pγH2AX positive cells per section with the addition of constant 1, n = 14–20. P = 0.016 (Ctrl Baseline vs. LDL Lowering), P = 0.0016 (Ctrl Baseline vs. Jak2 VF Baseline), P < 0.0001 ( Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (B, D, F, and H). DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; MFI, mean fluorescence intensity; MPN, myeloproliferative neoplasm; pγH2AX, phosphorylated histone H2A.X.

Journal: Journal of Lipid Research

Article Title: Aggressive cholesterol lowering normalizes atherosclerosis regression in Jak2 V617F mice

doi: 10.1016/j.jlr.2026.101003

Figure Lengend Snippet: Aggressive cholesterol lowering more strongly decreases macrophage pyroptosis and DNA damage in Jak2 VF MPN lesions. A: Images of aortic root lesions stained for MAC2 ( Green ), cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. B: Log 10 transformed cleaved GasD MFI in the necrotic core with the addition of constant 1, n = 14–20. P = 0.0064 for genotype effect and P = 0.021 for treatment effect by two-way ANOVA. C: Images of aortic root lesions stained for MAC2 ( Green ), Cleaved GasD ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , cleaved GasD + macrophages. D: Log 10 transformed cleaved GasD positive macrophages per section with the addition of constant 1, n = 13–20. P = 0.023 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.005 ( Jak2 VF Baseline vs. LDL Lowering). E: Representative immunoblot analysis of full-length and cleaved GasD in CD11b + splenocytes. F: Log 10 transformed densitometric quantification of the ratio of cleaved GasD to full-length GasD from E with the addition of constant 1. n = 7–8 biological replicates. P = 0.0003 (Ctrl Baseline vs. Jak2 VF Baseline), P = 0.0046 ( Jak2 VF Baseline vs. LDL Lowering). G: Images of aortic root lesions stained for MAC2 ( Green ), pγH2AX ( Red ), and DAPI ( Blue ). Scale bar, 60 μm. White arrows , pγH2AX positive cells. H: Log 10 transformed pγH2AX positive cells per section with the addition of constant 1, n = 14–20. P = 0.016 (Ctrl Baseline vs. LDL Lowering), P = 0.0016 (Ctrl Baseline vs. Jak2 VF Baseline), P < 0.0001 ( Jak2 VF Baseline vs. LDL Lowering). All quantifications shown as mean ± s.e.m. Two-way ANOVA with Tukey’s multiple comparisons test (B, D, F, and H). DAPI, 4′,6-diamidino-2-phenylindole; GasD, gasdermin D; LDL, low-density lipoprotein; MFI, mean fluorescence intensity; MPN, myeloproliferative neoplasm; pγH2AX, phosphorylated histone H2A.X.

Techniques: Staining, Transformation Assay, Western Blot, Fluorescence

Review

mac2 antibody (Cedarlane)

Structured Review

Images

Related Articles

other:

Immunohistochemistry:

Staining:

Similar Products

Image Search Results